| Unaudited Quarterly Results for the 3rd quarter and period ended 31st December 2003 |
| 1. |
The
above results were taken on record by the Board of Directors at
their meeting held on 31st January 2004. |
|
2. |
Consequent to subdivision of equity shares from Rs.10/- to
Rs.5/- each, the share data has been reclassified based on face
value of Rs.5/- each. |
| 3. |
Investor complaints pending at the beginning of the
quarter: Nil, received: 364, resolved: 348 and lying
unresolved at the end of the quarter: 16. |
| 4. |
Keeping
in view the Company's business model of vertical integration,
the management reviewed the reporting of its financial
results under one segment and accordingly the Company
reported its entire results under one segment viz
'Pharmaceutical Products'. |
| 5. |
Exports
constitute Rs.1645.4 million(Rs.1513.7 million) of the 3rd quarter
sales and Rs.4692.9 million (Rs.3989.2 million) of the nine months
sales. |
|